Bechini Angela, Salvati Cristina, Bonito Benedetta, Del Riccio Marco, Stancanelli Enrica, Bruschi Mario, Ionita Giulia, Iamarino Johanna, Bentivegna Davide, Buscemi Primo, Ciardi Giulia, Cosma Claudia, Stacchini Lorenzo, Paoli Sonia, Conticello Cristiana, Bega Manjola, Schirripa Annamaria, Bertizzolo Lorenzo, Muzii Barbara, Azzi Maria Vittoria, Parisi Salvatore, Trippi Francesca, Bonanni Paolo, Boccalini Sara
Department of Health Sciences, University of Florence, Florence, Italy.
Medical Specialisation School of Hygiene and Preventive Medicine, University of Florence, Florence, Italy.
Ann Ig. 2025 Mar-Apr;37(2):241-254. doi: 10.7416/ai.2024.2664. Epub 2024 Nov 7.
Respiratory syncytial virus is a leading cause of respiratory hospitalisations in infants. This systematic review (registration number: CRD42021248309) aims to synthesise the available evidence on Respiratory Syncytial Virus-related hospitalisations among children aged 0 to 6 years in Italy.
The literature search was conducted on PubMed, Embase, Scopus, and International HTA, covering the period from January 2000 to July 2022, with a focus on studies that reported information on Respiratory Syncytial Virus-associated hospitalisation in children aged 0-6 years in Italy.
Eight articles were included after screening 20,845 records. These retrospective studies reported that most hospitalisations were among those <1 year (71.5%-88.8%), infants aged <1 year were also at higher risk of hospitalisation in intensive care unit. Respiratory Syncytial Virus infections typically peaked December-February, with an atypical early start in August 2021. Subtype analysis showed alternating prevalence of Respiratory Syncytial Virus-A and Respiratory Syncytial Virus-B across different seasons. Coinfections were not uncommon (1.1%-37.4%), with rhinovirus and bocavirus being the most frequent.
All infants at their first Respiratory Syncytial Virus season showed an increased risk of severe infection and hospitalisation, regardless of the gestational age at birth, compared to older participants. This systematic review will enrich the understanding about Respiratory Syncytial Virus disease and help support decisions regarding prevention efforts in Italy.
呼吸道合胞病毒是婴儿因呼吸道疾病住院的主要原因。本系统评价(注册号:CRD42021248309)旨在综合意大利0至6岁儿童呼吸道合胞病毒相关住院的现有证据。
在PubMed、Embase、Scopus和国际卫生技术评估数据库进行文献检索,涵盖2000年1月至2022年7月期间,重点关注报告意大利0-6岁儿童呼吸道合胞病毒相关住院信息的研究。
在筛选20845条记录后纳入了8篇文章。这些回顾性研究报告称,大多数住院病例发生在1岁以下儿童中(71.5%-88.8%),1岁以下婴儿入住重症监护病房的住院风险也更高。呼吸道合胞病毒感染通常在12月至2月达到高峰,在2021年8月有一个非典型的早期开始。亚型分析显示,呼吸道合胞病毒A和呼吸道合胞病毒B在不同季节的流行交替出现。合并感染并不少见(1.1%-37.4%),鼻病毒和博卡病毒最为常见。
与年龄较大的参与者相比,所有处于首个呼吸道合胞病毒季节的婴儿,无论出生时的胎龄如何,发生严重感染和住院的风险均增加。本系统评价将丰富对呼吸道合胞病毒疾病的认识,并有助于支持意大利预防工作的决策。